日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

AD-214(一种用于治疗特发性肺纤维化的抗CXCR4 i-body-Fc融合蛋白)的开发和表征

Lynch Jason P, Organ Louise, Tomusange Khamis, Kowalczyk Lukasz, Hartman Dallas J, Tester Angus, Hosking Chris, Foley Michael

Correction: LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity

更正:体内LPS反应性和中性粒细胞趋化性需要PMN MMP-8活性。

Tester, Angus M; Cox, Jennifer H; Connor, Andrea R; Starr, Amanda E; Dean, Richard A; Puente, Xose S; López-Otín, Carlos; Overall, Christopher M

LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity

体内LPS反应性和中性粒细胞趋化性需要PMN MMP-8活性。

Tester, Angus M; Cox, Jennifer H; Connor, Andrea R; Starr, Amanda E; Dean, Richard A; Puente, Xose S; López-Otín, Carlos; Overall, Christopher M